TransCode Therapeutics Inc. (NASDAQ: RNAZ) completed its Phase 1a clinical trial for TTX-MC138, an experimental cancer treatment, meeting the primary ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE